Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces

Acta Pharmacologica Sinica

Volumn 32, Issue 5, 2011, Pages 655-663

  Xing, Jian Feng ^a   You, Hai Sheng ^a   Dong, Ya Lin ^a   Lu, Jun ^a   Chen, Si Ying ^a   Zhu, Hui Fang ^a   Dong, Qian ^a   Wang, Mao Yi ^a   Dong, Wei Hua ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

excretions; gender differences; metabolism; pharmacokinetics; scutellarein; scutellarin

Indexed keywords

SCUTELLAREIN; SCUTELLARIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EXCRETION; DRUG FECES LEVEL; DRUG MECHANISM; DRUG URINE LEVEL; FECES; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA; RAT; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE;

ADMINISTRATION, ORAL; ANIMALS; APIGENIN; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ERIGERON; FECES; FEMALE; GASTROINTESTINAL TRACT; GLUCURONIC ACIDS; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS;

EID: 79959726048     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.11     Document Type: Article

References (28)

1. 2+- mediated calcineurin and CaMKII signaling pathways. Naunyn Schmiedebergs Arch Pharmacol 2010; 381: 137-45.
2. Zhou QS, Zhao YM, Bai X, Li PX, Ruan CG. Effect of new-breviscapine on fibrinolysis and anticoagulation of human vascular endothelial cells. Acta Pharmacol Sin 1992; 13: 239-42.
3. Lin LL, Liu AJ, Liu JG, Yu XH, Qin LP, Su DF. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharmacol 2007; 50: 327-32.
4. Li Q, Wu JH, Guo DJ, Cheng HL, Chen SL, Chan SW. Suppression of diet-induced hypercholesterolemia by scutellarin in rats. Planta Med 2009; 75: 1203-8.
5. Pan Z, Feng T, Shan L, Cai B, Chu W, Niu H, et al. Scutellarin-induced endothelium-independent relaxation in rat aorta. Phytother Res 2008; 22: 1428-33. (Pubitemid 352789608)
6. Wang ZY, Chen DC, He Y, Ruan CG, Zhang RW. Differential effects of new breviscapine on arachidonic acid metabolisms in blood cells and endothelial cells. Acta Pharmacol Sin 1993: 14: 148-51. (Pubitemid 23113974)
7. Zhang GH, Wang Q, Chen JJ, Zhang XM, Tam SC, Zheng YT. The anti- HIV-1 effect of scutellarin. Biochem Biophys Res Commun 2005; 334: 812-6.
8. Tan ZH, Yu LH, Wei HL, Liu GT. The protective action of scutellarin against immunological liver injury induced by concanavalin A and its effect on pro-inflammatory cytokines in mice. J Pharm Pharmacol 2007; 59: 115-21. (Pubitemid 46133050)
9. Zhu JT, Choi RC, Li J, Xie HQ, Bi CW, Cheung AW, et al. Estrogenic and neuroprotective properties of scutellarin from Erigeron breviscapus: a drug against postmenopausal symptoms and Alzheimer's disease. Planta Med 2009; 75: 1489-93.
10. Zhu JT, Choi RC, Chu GK, Cheung AW, Gao QT, Li J, et al. Flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells a comparison of different flavonoids in activating estrogenic effect and in preventing beta-amyloid-induced cell death. J Agric Food Chem 2007; 55: 2438-45. (Pubitemid 46556236)
11. Sepehr E, Cooke G, Robertson P, Gilani GS. Bioavailability of soy isoflavones in rats Part I: application of accurate methodology for studying the effects of gender and source of isoflavones. Mol Nutr Food Res 2007; 51: 799-812 . (Pubitemid 47173690)
12. Lv W, Guo J, Ping Q, Song Y, Li J. Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats. Int J Pharm 2008; 359: 118-22.
13. Chen X, Cui L, Duan X, Ma B, Zhong D. Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration. Drug Metab Dispos 2006; 34: 1345-52. (Pubitemid 44079875)
14. You HS, Dong YL, Xing JF, Zhang CL, Wang MY. Pharmacokinetic and tissue distribution study of scutellarin in rats. Zhongguo Zhong Yao Za Zhi 2007; 32: 1688-92.
15. Liu Q, Shi Y, Wang Y, Lu J, Cong W, Luo G, et al. Metabolism profile of scutellarin in urine following oral administration to rats by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry. Talanta 2009; 80: 84-91.
16. Che QM, Chen Y, Pan LY, He H. Study on bile excretion of scutellarein. Zhongguo Zhong Yao Za Zhi 2006; 31: 1710-2.
17. Huang JM, Weng WY, Huang XB, Ji YH, Chen E. Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats. Eur J Drug Metab Pharmacokinet 2005; 30: 165-70. (Pubitemid 41499257)
18. Ju WZ, Zhang J, Tan HS, Jiang M, Chen M, Xiong NN. Determination of scutellarin in human plasma by LC-MS method and its clinical pharmacokinetics in Chinese healthy volunteers. Chin J Clin Pharmacol Ther 2005; 10: 298-301.
19. Zhang JL, Che QM, Li SZ, Zhou TH. Study on metabolism of scutellarin in rats by HPLC-MS and HPLC-NMR. J Asian Nat Prod Res 2003; 5: 249-56.
20. Hao X, Cheng G, Yu JE, He Y, An F, Sun J, et al. Study on the role of hepatic first-pass elimination in the low oral bioavailability of scutellarin in rats. Pharmazie 2005; 60: 477-8. (Pubitemid 40966309)
21. Huang M, Ho PC. Identification of metabolites of meisoindigo in rat, pig and human liver microsomes by UFLC-MS/MS. Biochem Pharmacol 2009; 77: 1418-28.
22. Sun Y, Cheng ZY, Zheng QS. Drug and Statistics Software (DAS), version 2.0. Mathematical pharmacology professional. Am J Pharm Edu 2005; 69: 397-8.
23. Shi SL, Xu LY, Mao ZK, Li WL, Ye JY, Gao M. Study on physicochemical properties and influence factors on stability of breviscapine. Zhongguo Zhong Yao Za Zhi 2009; 34: 843-7.
24. Xing J, Chen XY, Zhong DF. Stability of baicalin in biological fluids in vitro. J Pharm Biomed Anal 2005; 39: 593-600.
25. Huang J, Li N, Yu Y, Weng W, Huang X. Determination of aglycone conjugated metabolites of scutellarin in rat plasma by HPLC. J Pharm Biomed Anal 2006; 40: 465-71. (Pubitemid 43143357)
26. Slikker WJ, Scallet AC, Doerge DR, Ferguson SA. Gender-based differences in rats after chronic dietary exposure to genistein. Int J Toxicol 2001; 20: 175-9. (Pubitemid 32646168)
27. Wang R, Zhou S, Mei Q, Yang Z, Zhang BE, Liu Z. Study on gender-based differences in pharmacokinetics of genistein. Chin Phar J 2005; 40: 1575-8. (Pubitemid 41783512)
28. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009; 76: 215-28.